HomeClinical TopicsCardio-PulmonaryOff-label use of recombinant activated factor VII increases risk of arterial events

Off-label use of recombinant activated factor VII increases risk of arterial events

Off-label use of recombinant activated factor VII (rFVIIa) increases the risk of arterial but not venous thromboembolic events, particularly in older patients, according to an analysis of randomized clinical trials in the New England Journal of Medicine. Read more here.

Previous articleWho are you?
Next articlePropoxyphene taken off market

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

NP taking pregnant woman's blood pressure

AHA: It’s Safe to Treat High Blood Pressure During Pregnancy

High blood pressure during pregnancy can present significant risks to mother and child, but practitioners have sometimes be hesitant to prescribe blood pressure medication...